about
Phototheranostic Porphyrin Nanoparticles Enable Visualization and Targeted Treatment of Head and Neck Cancer in Clinically Relevant Models.Using molecular beacons for cancer imaging and treatment.Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agentsMultimodal bacteriochlorophyll theranostic agent.Transforming a Targeted Porphyrin Theranostic Agent into a PET Imaging Probe for Cancer.Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activation.Porphyrin Nanodroplets: Sub-micrometer Ultrasound and Photoacoustic Contrast Imaging Agents.Investigating the specific uptake of EGF-conjugated nanoparticles in lung cancer cells using fluorescence imaging.Nanoparticle-Enabled Selective Destruction of Prostate Tumor Using MRI-Guided Focal Photothermal Therapy.Tailoring nanoparticle designs to target cancer based on tumor pathophysiology.Ablation of hypoxic tumors with dose-equivalent photothermal, but not photodynamic, therapy using a nanostructured porphyrin assembly.Topical MMP beacon enabled fluorescence-guided resection of oral carcinoma.Killer beacons for combined cancer imaging and therapy.Biologically-targeted detection of primary and micro-metastatic ovarian cancerPhotodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers.Activatable photosensitizers for imaging and therapy.Peptide-based molecular beacons for cancer imaging and therapy.Lipid-based nanoparticles in the systemic delivery of siRNA.Learning from biology: synthetic lipoproteins for drug delivery.Theranostic lipid nanoparticles for cancer medicine.Multimodal Image-Guided Surgical and Photodynamic Interventions in Head and Neck Cancer: From Primary Tumor to Metastatic Drainage.Organized Aggregation of Porphyrins in Lipid Bilayers for Third Harmonic Generation Microscopy.A PEGylation-Free Biomimetic Porphyrin Nanoplatform for Personalized Cancer Theranostics.Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency.Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model.Targeting-triggered porphysome nanostructure disruption for activatable photodynamic therapy.Optical glucose analogs of aminolevulinic acid for fluorescence-guided tumor resection and photodynamic therapy.Matrix metalloproteinase-based photodynamic molecular beacons for targeted destruction of bone metastases in vivo.Nanotexaphyrin: One-Pot Synthesis of a Manganese Texaphyrin-Phospholipid Nanoparticle for Magnetic Resonance Imaging.Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology.Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide--phospholipid nanoscaffold.Imaging of specific activation of photodynamic molecular beacons in breast cancer vertebral metastases.Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles.Cytosolic delivery of LDL nanoparticle cargo using photochemical internalization.HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting.Biomimetic nanocarrier for direct cytosolic drug delivery.Synthesis and evaluation of a stable bacteriochlorophyll-analog and its incorporation into high-density lipoprotein nanoparticles for tumor imaging."Zipper" molecular beacons: a generalized strategy to optimize the performance of activatable protease probes.FRET quenching of photosensitizer singlet oxygen generation.A tumor mRNA-triggered photodynamic molecular beacon based on oligonucleotide hairpin control of singlet oxygen production.
P50
Q30395878-7F2E2DD1-D2C8-488D-A556-76895210FC60Q33283917-299A955C-3074-45FE-AAD3-3A2939BD1E39Q35082176-EFE4DEC6-D028-4F6D-8207-F4284FAAFEFEQ35224467-E994D991-1249-4E08-AC18-C800ED038A78Q35224469-09961600-35DB-41D3-8518-73A9A4581365Q35793230-1918F5A6-07A0-45D5-8748-80A8BC3C7309Q35860193-26928864-B17E-4F0E-9F28-AAA5B2E20A23Q35979595-165AAA1E-734B-4C36-9770-A5CEF51507EBQ36023165-52FD9365-FB87-4C75-8B7D-00DC2ACF5488Q36659002-C503F6ED-741F-4118-B023-7877D5ED289AQ36723250-17651552-8347-41BC-998C-64AD941FFFC1Q36899649-EE948F6A-A62E-456B-B456-A43C297A5426Q36907316-97824C68-6E66-4A89-A1FE-9838CBD2FF89Q36915331-E1586807-FACF-47D0-9CBE-778628AEB02CQ37411837-1F06497B-C351-42DB-AAD5-52811DDCB42BQ37682213-3A6F1FD0-15C7-47A9-B9AE-33C748538232Q37695129-C3DBFBC3-131E-4F30-9F37-24C75CA12163Q38172634-F785648E-1D2A-4DF4-925B-D2B090810F94Q38262882-C2AEBAF5-0495-4316-9E29-675F8253D664Q38431560-D2517E6C-E115-4C7F-961C-F62449908A41Q38828165-484D48DA-5967-4F47-B9B0-290257CE1873Q38831549-89B60E18-92D7-412C-979E-1CE48BCCA160Q38892224-00886B8A-9CA5-474F-8D64-A2038A729A10Q38995658-05E9575D-DD74-4068-807B-83849201EB26Q39007153-BD2F5922-B3E5-43C1-8B65-E7D553BC4058Q39030427-42C69CBD-F69A-4504-A149-F4D8F93A993AQ39045026-972CB81F-4CD9-4F56-8E54-64BDFECA0154Q39176626-A16C72E9-1190-4793-BEA0-33809523CC31Q39289752-D56BB9B3-FBD8-4412-8A47-7A96B72FD5C0Q39458112-95D87D0E-759B-47C5-A246-84FA95544DFFQ39515377-5795877C-0E49-44F0-8A26-92E272828A5DQ39541115-455EE367-C939-4804-8C03-59EABC69E9E8Q39582387-5B8435CF-936B-4A1E-A9BF-C8611C8FC899Q39587660-A38ED8B2-3FDA-49FD-A145-C1E8B267B675Q39767578-4403A95C-1AF8-48B0-8B51-A41D39DE47B9Q39781640-51BFA6FF-2A46-4C43-8CC4-76658DF1DF71Q39785997-395F611B-2EA2-4DA6-B652-479BD7B9355DQ39799703-6B3F31C4-C90E-4000-B6FA-249BF0988CF1Q39808034-0F2145F6-B2E6-4A35-88A5-B7514850DA28Q39965932-E98E8B50-5C8F-4D6C-8A71-D0C0539A0F57
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Juan Chen
@ast
Juan Chen
@de
Juan Chen
@en
Juan Chen
@es
Juan Chen
@fr
Juan Chen
@nds
Juan Chen
@nl
Juan Chen
@sl
type
label
Juan Chen
@ast
Juan Chen
@de
Juan Chen
@en
Juan Chen
@es
Juan Chen
@fr
Juan Chen
@nds
Juan Chen
@nl
Juan Chen
@sl
prefLabel
Juan Chen
@ast
Juan Chen
@de
Juan Chen
@en
Juan Chen
@es
Juan Chen
@fr
Juan Chen
@nds
Juan Chen
@nl
Juan Chen
@sl
P108
P106
P21
P31
P496
0000-0001-7515-5072